The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.
The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology. Complications may include arterio-veinous fistula or graft (AVF or AVG) thrombosis with or without known stenosis; AVF or AVG or central veinous catheter (CVC) infections and CVC dysfunctions. The investigators may enroll all patients receveing therapeutic apheresis for nephrologic indications in North East France. Nephrologics indications include : * acute or active antibody mediated rejection (ABMR), * Goodpasture disease, * ANCA vasculitis, * thrombotic microangiopathy (TMA), * Focal segmental glomerulosclerosis (FSGS), * HLA or ABO desensitization for kidney transplantation. Data inclusion period is from June 2020 to June 2022. The aim of the study is to describe the proportion and type of complication in the population of patient receving therapeutic apheresis for nephrologic disease in the North East France. Te investigators will study the risk factors that are associated with this complications. The second aim of the study is to describe the population of patient receving therapeutic apheresis in our unit and in our region.
Study Type
OBSERVATIONAL
Enrollment
60
Central Hospital
Nancy, France
Vascular access Complication (catheter or AVF/AVG thrombosis/infection) rate in therapeutic apheresis among nephrological diseases
Percent of patient with Vascular access Complication
Time frame: june 2020 june 2022
Description of population enrolled
Description of population treated by therapeutic apheresis in Northeast France
Time frame: june 2020 june 2022
Comparison of complications rate with literature datas
Time frame: june 2020 june 2022
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.